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 ABSTRACT
Introduction: Renal biopsy plays an essential role either in the diagnosis or in the prognosis of patients with 
renal disease. In order to assess its epidemiology and evolution in Madeira Islands, we analysed twenty-seven 
years of native kidney biopsies. Methods: We performed a retrospective analysis of clinical records, including 
histological revision from 1986 to 2012, totalling 315 native kidney biopsies. They were assessed regarding the 
temporal evolution both for the quality/indications for renal biopsy and for the patterns of kidney disease. 
Results: A total of 315 native kidney biopsies were analysed. The patients’ mean age was of 40.8 ± 18.4 years 
and 50.5%(n = 159) were males. The most common indications for renal biopsy were nephrotic syndrome 
(36.2%, n = 114) and acute kidney injury (20.0%, n = 63). Among primary glomerular diseases (41.5%, n = 
115) the most common were IgA nephropathy (26.1%, n = 30) and focal-segmental glomerulosclerosis (17.4%, 
n = 20) and among secondary glomerular diseases (31.4%, n = 87), lupus nephritis (51.7%, n = 45) and amy-
loidosis (20.7%, n = 18). Statistical analysis revealed significant correlation between gender and major patho-
logical diagnosis (Fisher’s exact test, p <.01) and between indications for renal biopsy and major pathological 
diagnosis (χ2, p <.01). Regarding the temporal evolution, no statistically significant differences were found in 
the number of renal biopsies (χ2, p =.193), number of glomeruli per sample (Fisher’s exact test, p =.669), age 
(Kruskal-Wallis, p =.216), indications for renal biopsy (χ2, p =.106) or major pathological diagnosis groups (χ2, 
p =.649). However, considering the specific clinico-pathological diagnoses and their temporal variation, a sta-
tistically significant difference (Fisher’s exact test, p <.05) was found for lupus nephritis and membranous 
nephropathy with an increasing incidence and for amyloidosis with an opposite tendency. Discussion: The 
review of the native kidney biopsies from a population with particular characteristics, geographically isolated, 
such as those from Madeira Islands, showed parallel between epidemiological numbers referring to other 
European subpopulations, allowing simultaneously a comprehensive approach to our renal biopsy policies.
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 RESUMO
Introdução: A biópsia renal é fundamental na abordagem diagnóstica e no prognóstico de doentes com 
patologias nefrológicas. No sentido de avaliar a epidemiologia das doenças renais na Região Autónoma da 
Madeira e a sua evolução, analisou-se as biópsias de rim nativo nos últimos vinte e sete anos. Métodos: 
Procedeu-se à análise retrospectiva dos registos e lâminas histológicas de 1986-2012, com avaliação da 
evolução temporal na qualidade/indicações para biópsia renal e padrões de patologias nefrológicas. Resul-
tados: A amostra compreende 315 biópsias de rim nativo, sendo a idade média dos doentes de 40.8 ± 18.4 
anos, sendo 50.5% (n = 159) do sexo masculino. As síndromes nefrológicas mais frequentes foram a sín-
drome nefrótica (36.2%, n = 114) e lesão renal aguda (20.0%, n = 63). Das patologias nefrológicas mais 
frequentes, destacam-se no grupo das glomerulopatias primárias (41.5%, n = 115), a nefropatia de IgA 
(26.1%, n = 30) e a glomeruloesclerose segmentar e focal (17.4%, n = 20) e nas glomerulopatias secundárias 
(31.4%, n = 87), a nefrite lúpica (51.7%, n = 45) e amiloidose (20.7%, n = 18). Na análise estatística, 
realça-se a correlação significativa entre sexo e grupos de síndromes nefrológicas (Fisher’s exact test, p 
<.01) e entre grupos de síndromes nefrológicas e diagnóstico patológicos (χ2, p <.01). Avaliando a evolução 
temporal, não se objectivaram diferenças estatisticamente significativas em relação ao número de biópsias 
renais (χ2, p =.193), número de glomérulos na amostra (Fisher’s exact test, p =.669), idade (Kruskal-Wallis, 
p =.216), síndromes nefrológicas (χ2, p =.106) ou grandes grupos de diagnóstico patológicos (χ2, p =.649). 
No entanto, considerando os dignósticos patológicos específicos e a sua variação temporal foram encon-
tradas diferenças significativas (Fisher’s exact test, p <.05) para nefrite lúpica e nefropatia membranosa com 
uma incidência crescente e para a amiloidose com uma tendência oposta. Discussão: A análise do registo 
de biópsias renais de uma população com características particulares, isolada geograficamente, permitiu 
mostrar concordância com outros números epidemiológicos referentes a outras subpopulações europeias, 
permitindo simultaneamente uma compreensão das directrizes locais sobre biópsias renais.
Palavras-chave: Biópsia renal; doença renal; epidemiologia; glomerulonefrite; nefropatia.
 INTRODUCTION
Renal biopsy was introduced into regular clinical 
practice in the early 1950s and, since then, it has 
become an essential tool in assessing the diagnosis, 
providing information of prognostic value and guid-
ing the treatment of patients with renal disease1. 
However, given its invasive nature and despite the 
advances in the renal biopsy technique with the 
development and utilization of real-time ultrasound 
guidance and automated biopsy needles2 there are 
still inherent risks and one must balance the pros 
and cons considering each patient. In a broader 
perspective, reviewing the epidemiology of renal 
diseases besides assessing its incidence, prevalence 
and trends may help to identify environmental or 
genetic factors contributing towards disease develop-
ment and other relevant demographical, clinical and 
histological features, as well as the influence from 
single-centre biopsy policies.
Given the particular characteristics of the Madei-
ra Islands, an archipelago geographically isolated 
in the North Atlantic Ocean comprising about 
250,000 inhabitants, a virtually self-contained com-
munity with only one major medical provider facility 
makes it exceptionally suited for these observa-
tional studies. Therefore, we reviewed twenty-
seven years’ experience of native kidney biopsies 
in order to assess its renal disease epidemiology 
and evolution.
 SUBJECTS AND METHODS
This retrospective study identified all patients for 
whom a native kidney biopsy was performed, between 
January 1986 and December 2012, in the Nephrology 
Department of Hospital Central do Funchal, the single 
referral nephrology centre for Madeira Islands. During 
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this time period, a total of 315 native kidney biopsies 
were performed, including children (< 16 years) and 
adult patients (≥ 16 years).
The renal biopsy technique in our centre has 
evolved during the time period the study refers to. 
In the beginning, the technique used was by com-
puterized tomography marking and then the biopsy 
itself was accomplished using a 14G Vim Silverman 
needle. Since 1995, we started using a standard 
real-time ultrasound-guided technique with an auto-
mated spring-fired biopsy gun and a 14G disposable 
needle (Bard Biopsy Systems®, Bard, UK). All renal 
biopsy specimens were then dispatched along with 
the clinical information (medical history, physical 
examination and laboratory data) and analysed at a 
Renal Pathology Laboratory in Curry Cabral Hospital, 
Lisbon. All biopsy specimens were evaluated by opti-
cal microscopy and immunofluorescence (IF) when-
ever possible, using standard procedures. Electron 
microscopy was available only for selected cases. 
The renal biopsies were studied by means of routine 
staining: haematoxylin-eosin, periodic acid-Schiff, 
Masson’s trichrome and methenamine silver and, in 
selected cases, with other histochemical stains. For 
cases without adequate frozen tissue for IF, the 
formalin-fixed, paraffin-embedded renal tissue was 
used for IF.
For each case, final diagnosis was then estab-
lished concerning the correlation between both 
clinical and histological investigations. The reports 
were then forwarded back to the referring neph-
rologist and the renal biopsy specimens were stored 
in case future revision was needed. From the clinical 
information provided, an indication for biopsy was 
determined, according to the following clinical 
syndromes3:
1. Nephrotic syndrome (NS): defined as proteinuria 
> 3.5 g/d with hypoalbuminemia (serum albumin 
< 2.5 g/dl) with or without peripheral oedema;
2. Nephritic syndrome (NiS): defined as haematu-
ria, hypertension, oedema and reduced glo-
merular filtration rate (GFR);
3. Asymptomatic urinary abnormalities (AUA): pro-
teinuria < 3.5 g/d and/or haematuria with more 
than 3 red blood cells per field without clinical 
manifestations;
4. Acute kidney injury (AKI): rapid deterioration 
of GFR, including “acute on chronic”, with or 
without oligoanuria or rapidly progressive renal 
failure;
5. Chronic kidney disease (CKD): decline in renal 
function less severe and/or less abrupt than 
defined for AKI, with or without proteinuria 
and/or haematuria. (Patients with NS and chron-
ic-progressive kidney injury were categorized 
under NS)
The histological findings were classified as follows, 
using a modified classification scheme of World 
Health Organization recommendations4-6:
1. Primary glomerulonephritis (GN): minimal change 
disease (MCD), focal segmental glomeruloscle-
rosis (FSGS), membranous nephropathy (MN), 
IgA nephropathy (IgAN), mesangioproliferative 
GN other than IgAN (MesGN), crescentic GN 
(CrGN)(not fulfilling the criteria for systemic dis-
ease), membranoproliferative GN (MPGN) and 
proliferative endocapillary GN (PEGN);
2. Secondary GN: lupus nephritis (LN), systemic 
vasculitis (VAS), anti-glomerular basement 
membrane disease (antiGBM), Henoch-Schön-
lein purpura (HSP), renal amyloidosis and GN 
caused by dysgammaglobulinaemia or parapro-
teinaemia, such as light-chain deposit disease 
(LCDD), myeloma kidney (MM), essential cryo-
globulinaemia and Waldenstrom’s macroglobu-
linaemia, diabetic nephropathy (DN), GN associ-
ated with infectious diseases (non-streptoccocal 
GN, endocarditis, shunt GN and others) and 
hereditary GN;
3. Tubulointerstitial diseases, including acute and 
chronic tubulointerstitial nephritis and acute 
tubular necrosis;
4. Vascular diseases, including benign and malig-
nant nephroangiosclerosis (NAS), thrombotic 
microangiopathy and cortical necrosis;
5. Other findings including end-stage renal disease 
(ESRD) of undetermined cause, unclassified 
nephropathies, others such as pregnancy relat-
ed nephropathies, rare nephropathies and nor-
mal renal tissue samples.
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 STATISTICAL ANALYSIS
Statistical analysis was performed using SPPS, 
version 17.0 (SPSS, Chicago, IL), considering three 
inclusive 9-year time frames: 1986–1994, 1995–2003 
and 2004–2012. Chi-square test and Fisher’s exact 
test were used for categorical variables, and Kruskal-
Wallis test for ordinal variables. P-values <.05 were 
considered statistically significant.
 RESULTS
Over the 27 year study, a total of 315 renal biop-
sies were performed, totalling 295 patients given 
that 20 records were identified as re-biopsy, with 10 
of these carried out due to inadequate sampling 
during the first biopsy, and 10 for therapeutic/diag-
nostic reasons at different time points of follow-up 
(range 6–118 months). The incidence of renal biop-
sies, considering the 9-year time frames varied 
between 53.3 per million population (p.m.p.)/year in 
1986–1994 to 42.6 p.m.p./year in 1995–2003 and to 
44.0 p.m.p./year in 2004–2012, though there were 
no statistically significant differences (χ2, p =.193). 
In what concerns sampling adequacy, renal tissue 
was obtained in 277 renal biopsies (87,9%) and in 
spite of the changing renal biopsy technique, no 
statistical differences were found concerning the 
number of glomeruli per sample (Fisher’s exact test, 
p =.669). Regarding the demographic variables, the 
patients’ mean age was of 40.8 ± 18.4 years and 
50.5% (n = 159) were male, including children < 16 
years (n = 17, 5.4%). The patients’ mean age was 
compared according to the previously established 
time-frames, but no significant variability was found 
(Kruskal-Wallis, p =.216).
The most common indications for a biopsy were 
NS (n = 114, 36.2%) and AKI (n = 63, 20.0%) fol-
lowed by CKD (n = 55, 17.5%), AUA (n = 42, 13.3%) 
and NiS (n = 41, 13.0%) and once more the time-
framed analysis showed no statistically significant 
differences (χ2, p =.106) (Fig. 1).
The frequency of the clinico-histological diagnoses 
is shown in Table I. Overall, among the major patho-
logical groups, primary GN was the most common 
diagnosis (41.5%), followed by secondary GN (31.4%), 
tubulointerstitial diseases (7.6%), vascular diseases 
(3.6%) and other findings (15.9%). Considering the 
specific diagnosis, the most common type of primary 
GN were IgAN (n = 30, 26.1%), FSGS (n = 20, 17.4%) 
and MCD (n = 19, 16.5%) and amid the secondary 
GN the most common were LN (n = 45, 51.7%), 
amyloidosis (n = 18, 20.7%) and DN (n = 11, 12.6%). 
In view of the temporal evolution, according to the 
time-frames previously established, no statistically 
significant differences were found regarding the major 
pathological groups (χ2, p =.649). Considering the 
specific clinico-pathological diagnoses, its distribution 
according to temporal evolution is shown in Fig. 2 
and taking into account the statistical analysis of the 
most common types of specific diagnoses, the tem-
poral evolution shows a statistically significant dif-
ference (Fisher’s exact test, p <.05) only for LN and 
MN with an increasing incidence and for amyloidosis 
with an opposite tendency. For informational purposes 
we have subdivided LN and amyloidosis according 
Figure 1
Indications for biopsy according to 9-year time frames
NS nephritic syndrome; AKI acute kidney injury; CKD chronic kidney disease; AUA asymptomatic urinary abnormalities; NiS nephritic syndrome
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Figure 2
Specific clinico-pathological diagnoses according to 9-year time frames.
*(p<.05)
IgAN IgA nephropathy; ESRD end-stage renal disease; FSGS focal segmental glomerulosclerosis; MCD minimal change disease; MN membranous nephropathy; TIN tubulointersti-
tial nephropathy; PEGN proliferative endocapillary glomerulonephritis; DN diabetic nephropathy
Table I
Clinico-histological diagnoses (major pathological groups and specific diagnosis) by age group 
adults n = 262 (83.2%) children n = 17 (5.4%)
elder (age ≥ 65 yrs) 
n=36 (11.4%)
total
% of the 
major 
group
subtotal m f subtotal m f subtotal m f
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Primary GN 115 (41.5) n = 92 54 (58.7) 38 (41.3) n = 10 7 (70.0) 3 (30.0) n = 13 7 (53.8) 6 (46.2)
IgAN 30 (10.8) 26.1 27 19 8 2 1 1 1 1 0
FSGS 20 (7.2) 17.4 16 11 5 3 1 2 1 0 1
MCD 19 (6.9) 16.5 14 4 10 2 2 0 3 1 2
MN 16 (5.8) 13.9 12 7 5 1 1 0 3 1 2
PEGN 12 (4.4) 10.4 9 6 3 1 1 0 2 2 0
MPGN 7 (2.5) 6.1 6 1 5 – – – 1 1 0
MesGN 7 (2.5) 6.1 6 5 1 1 1 0 – – –
CrGN 4 (1.4) 3.5 2 1 1 – – – 2 1 1
Secondary GN 87 (31.4) n = 76 17 (22.4) 59 (77.6) n = 1 1 (100.0) 0 (0.0) n = 10 4 (40.0) 6 (60.0)
Lupus nephritis 45 (16.2) 51.7 44 4 40 1 1 0 – – –
Amyloidosis 18 (6.5) 20.7 12 4 8 – – – 6 2 4
Diabetic nephropathy 11 (4.0) 12.6 8 3 5 – – – 3 1 2
Systemic vasculitis 4 (1.4) 4.6 3 0 3 – – – 1 1 0
HSP 2 (0.7) 2.3 2 1 1 – – – – – –
Cryoglobulinaemic GN 1 (0.4) 1.2 1 0 1 – – – – – –
Other 6 (2.2) 6.9 6 5 1 – – – – – –
Tubulointerstitial diseases 21 (7.6) n = 14 8 (57.1) 6 (42.9) n = 0 – – n = 7 5 (71.4) 2 (28.6)
Chronic tubulointerstitial nephritis 13 (4.7) 61.9 10 5 5 – – – 3 3 0
Acute tubulointerstitial nephritis 5 (1.8) 23.8 3 2 1 – – – 2 1 1
Acute tubular necrosis 3 (1.1) 14.3 1 1 0 – – – 2 1 1
Vascular diseases 10 (3.6) n = 9 4 (44.4) 5 (55.6) n = 0 – – n = 1 0 (0.0) 1 (100.0)
Hypertensive nephroangiosclerosis 8 (2.9) 80.0 7 4 3 – – – 1 0 1
Thrombotic microangiopathy 2 (0.7) 20.0 2 0 2 – – – – – –
Other 44 (15.9) n = 39 27 (69.2) 12 (30.8) n = 3 – – n = 2 2 (100.0) 0 (0.0)
ESRD (undetermined cause) 22 (7.9) 50.0 20 15 5 – – – 2 2 0
Unclassified nephropathies 5 (1.8) 11.4 5 4 1
Normal renal tissue 17 (6.2) 38.6 14 8 6 3 1 2
(no kidney sample) 38 32 3 3
GN glomerulonephritis; IgAN IgA nephropathy; FSGS focal segmental glomerulosclerosis; MCD minimal change disease; MN membranous nephropathy; PEGN proliferative endo-
capillary GN;MPGN membranoproliferative GN; MesGN mesangioproliferative GN other than IgAN; CrGN crescentic GN; LN Lupus nephritis; HSP Henoch-Schönlein purpura.
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to classes and subtypes, respectively. Among LN, the 
histopathological classes most found were class IV 
(51.1%), class II (26.7%) and class III (17.8%) and as 
amyloidosis is referred AA subtype (66.7%) and AL 
(22.2%) were the most frequent. Once we had estab-
lished a decreasing incidence of amyloidosis, we 
analysed the subset of AA, AL and other amyloidosis 
for temporal variation having found no statistically 
significant differences (p =.14, p =.74 and p =.34, 
respectively). Correlations between gender, indica-
tions for renal biopsy and clinico-histological diag-
noses are shown in Table II and, as one can observe, 
statistically significant differences were found between 
gender and major pathological diagnoses (Fisher’s 
exact test, p <.01) and between indications for renal 
biopsy and major pathological diagnosis (χ2, p <.01).
 DISCUSSION
This retrospective study enables a comprehensive 
approach to our centre biopsy policies and their adjust-
ments in the past twenty-seven years. According to the 
demographical and clinical analysis, we found no sta-
tistically significant differences in what concerns number 
of biopsies performed, sampling adequacy and indica-
tions for biopsy. This may suggest, on one hand, a 
stable approach and workup for nephropathies and, 
acknowledged the indispensable evolution in the kidney 
biopsy technique, that the sampling adequacy kept the 
same standards. On the other hand, given the small 
sized sample the detection of any underlying statisti-
cally significant differences may be underpowered. 
Regarding the renal biopsy rate in our study, the num-
bers are quite similar to those described in almost all 
European registries (48 p.m.p./year in Spain7, 34 p.m.p./
year in Italy6, 16.3–20.1 p.m.p./year in France8, 44.1–69.3 
p.m.p./year in the Czech Republic9, 40 p.m.p./year in 
Denmark10 and to those of our own national registry, 
61.4 p.m.p./year in 2011-2012) apart from some registries 
whose numbers are somewhat uneven due to particular 
reasons (10.8 p.m.p./year en Serbia11, 10.7-12.8 p.m.p./
year in Romania12, 126.3 p.m.p./year in Scotland13 and 
176 p.m.p./year in Finland14. Whereas indications for 
biopsy are concerned, NS was our most frequent clinical 
presentation as in some other registries (7, 9, 11, 12), 
however we found some divergences with other reg-
istries as the AUA came responsible only for 13.3% 
while in many other studies it imposed itself as a more 
frequent indication for biopsy (24.3-38.7%)(6, 7, 9, 11, 
14). This may foretell a somewhat conservative approach 
Table II
Correlations between gender, indications for renal biopsy and clinico-histological diagnoses
Gender Indications for renal biopsy (χ2, p =.908)
NS NiS AUA AKI CKD total
male 56 21 19 33 30 159
female 58 20 23 30 25 156
total 114 41 42 63 55 315
Gender Major pathological diagnosis (Fisher’s exact test, p <.01)
primary GN secondary GN TI diseases Vasc diaseases Other total
male 68 20 13 4 31 136
female 47 67 8 5 14 141
total 115 87 21 9 45 277
Indications for 
renal biopsy
Major pathological diagnosis (χ2, p <.01)a
primary GN Secondary GN TI diseases Vasc diaseases Other total
NS 61 32 2 1 11 107
NiS 14 6 4 4 5 33
AUA 20 7 0 0 8 35
AKI 17 22 8 1 5 53
CKD 3 20 7 3 16 49
115 87 21 9 45 277
a TI/Vasc diseases were not considered for statistical analysis due to small sized sample
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at our centre in terms of kidney biopsy as the workup 
for these clinical presentations or, as Okpechi suggests, 
it may reflect healthcare investment15. Our report shows 
that, among the major pathological groups, primary 
GN stands as the most common (41.5%), followed by 
secondary GN (31.4%) what mirrors other registries’ 
results where primary GN varies between 51.5-64.1%(6-
9, 11, 12) and secondary GN between 20.4-26.4%(6, 7, 
9, 11, 12). Addressing the specific diagnosis analysis 
we recognized IgAN (26.1%) as the most common pri-
mary GN, as in other European subpopulations (6-9, 
14), and LN (51.7%) as the most frequent among the 
secondary GN going in line not only with European 
subpopulations, but also with worldwide biopsy-proven 
glomerular diseases16, both of which go according to 
our own national registry.
Deliberately, we have revised the Canary Islands’ 
Registry of renal biopsies (17, 18) separately, since it 
somehow presents with similar characteristics to those 
of our own. As a result, we found parallel epidemiologi-
cal data among pathological groups, with primary GN 
attaining top place with 39.8%, and its subset of specific 
diagnosis showing also similar distribution with IgAN 
being the most frequent (36.6%), followed by MCD 
(18.1%) and FSGS (17.1%), with the latter two assuming 
an inverse order when compared to our data. However, 
we would like to draw attention to the differences 
found in the prevalence of certain glomerulopathies 
among different provinces in the Canary Islands, mainly 
as FSGS is concerned, what seems to be related to a 
different genetic load on each province and set the 
authors in search of genetic mutations17.
Examining the results of the epidemiological analysis 
in relation to temporal variation we found no significant 
differences in the major pathological diagnoses, none-
theless, considering the most common specific diag-
noses and assessing their variation along the time 
periods we found, on the one hand, statistically sig-
nificant increasing incidence in biopsy-proven LN and 
MN and, on the other, decreasing incidence among 
amyloidosis. Focusing on the absence of temporal vari-
ation of IgAN’s incidence, as shown in other series 19, 
this may reflect once more the conservative biopsy 
policies. Then again, LN’s raise is probably due to both 
low nephrology referral in the early period the study 
refers to and re-biopsying relapses for therapeutic pur-
poses, while the increasing incidence in MN is some-
what similar to that described in other registries (6, 
7). Taking into consideration the decreasing incidence 
of amyloidosis, the subset analysis for amyloidosis 
(AA, AL and others) despite not having found statistical 
significance among them, demonstrated a higher ten-
dency (p =.14) for amyloidosis AA as being the reason 
for the decline for amyloidosis. This decline in the 
incidence of amyloidosis contrasts with the results of 
the Italian Registry 20 but goes along with those from 
Spain21. In our study, the decrease is mainly justified 
by the AA form, what previous studies(21, 22) suggest 
being due to advances in the treatment of chronic 
infections and autoimmune inflammatory diseases, thus 
reflecting an increasing healthcare investment and leav-
ing the aforementioned AUA’s low prevalence as indi-
cation for kidney biopsy as probably resulting from a 
conservative approach at our centre. In the course of 
the subset analysis of amyloidosis, the recognition of 
four cases of AL amyloidosis caught our eye as none 
of “myeloma kidney” or cast nephropathy was diag-
nosed. Such result discloses that the true prevalences 
of different kidney diseases are not always represented 
by biopsy rates, once cast nephropathy is considered 
the most common renal pathology in myeloma 
patients23. However, one must bear in mind that in 
the case of myeloma patients with cast nephropathy 
their common clinical contraindications and sometimes 
presumptive diagnosis avert the definitive diagnosis 
made by renal biopsy, justifying the discrepancy by 
one side with necropsy results (11% cases of AL amy-
loidosis vs. 32% cases of cast nephropathy) 24 that 
reflect more truthful prevalences in opposition to renal 
biopsy database’s revision results (68% cases of AL 
amyloidosis vs. 17% cases of cast nephropathy)25.
Another finding that drew our attention was that 
of two cases of TI nephritis presenting with NS (Table 
II). Although the histological analysis revealed no more 
than tubular and interstitial changes, the NS suggests 
the presence of glomerular pathology, thus we thought 
further individual consideration on these two cases 
was imperative. Considering the first of the two, an 
acute interstitial nephritis was clinically interpreted 
as a case of NSAID’s nephropathy, thus justifying the 
association with NS as in patients who develop both 
AIN and minimal change disease(26-28). These cases 
usually conceal extensive foot process effacement only 
revealed by electron microscopy that was not per-
formed in this particular situation justifying, therefore, 
the non-description of glomerular changes by optical 
microscopy26. The latter was histologically character-
ized as a chronic interstitial nephritis but no aetiology 
was clinically plain. In this case, we can only consider 
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a possible sampling bias as only 4 glomerulus were 
present, what might withhold the finding of glomerular 
sclerosis in the context of CIN.
Although a broader analysis could enhance our 
epidemiology knowledge of this geographical region, 
in view of such a small sample an in depth analysis 
of temporal evolution, covering all clinico-histological 
diagnoses rendered itself unattainable.
 CONCLUSION
This study allowed us, on the one hand, to acknowl-
edge comprehensively our centre biopsy policies and 
on other to render information that, despite the geo-
graphical isolation of Madeira Islands, showed that 
the demographical and clinical data of renal diseases 
is in many aspects similar to that from other European 
subpopulations. However, as in other similar regions 
it may conceal some endemic mutations.
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